Condition: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) · Pulmonary Arterial Hypertension (PAH) · Pulmonary Arterial Hypertension · Sponsor: University of Sao Paulo General Hospital
Pulmonary arterial hypertension (PAH) is a progressive condition with high morbidity, frequent hospitalizations, and risk of right heart failure. Despite advances in treatment, poor adherence remains a major challenge. This randomized controlled study assesses whether remote monitoring can improve treatment adherence, clinical outcomes, and side effect management in PAH patients on oral therapy.
This description comes directly from the study's public registry record.
Caio Fernandes, PhD · +55 11 2661-1548 · caio.cesar@hc.fm.usp.br
Always discuss trial participation with your own doctor first.
| InCor - Universidade de São Paulo | São Paulo, São Paulo, Brazil | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06850792